{"Symbol": "ADIL", "AssetType": "Common Stock", "Name": "Adial Pharmaceuticals Inc", "Description": "Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.", "CIK": "1513525", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "4870 SADLER ROAD, GLEN ALLEN, VA, UNITED STATES, 23060", "OfficialSite": "https://www.adial.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "3166800", "EBITDA": "-7854250", "PERatio": "None", "PEGRatio": "None", "BookValue": "4.725", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-15", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.794", "ReturnOnEquityTTM": "-1.55", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-15", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "26", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "2", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "0.688", "EVToRevenue": "-", "EVToEBITDA": "-0.491", "Beta": "1.237", "52WeekHigh": "32.5", "52WeekLow": "2.7", "50DayMovingAverage": "5.72", "200DayMovingAverage": "9.4", "SharesOutstanding": "1111200", "SharesFloat": "954940", "PercentInsiders": "2.081", "PercentInstitutions": "3.759", "DividendDate": "None", "ExDividendDate": "None"}